Journal
CANCER RESEARCH
Volume 80, Issue 3, Pages 624-638Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-19-1840
Keywords
-
Categories
Funding
- NHMRC
- National Breast Cancer Foundation
- Cancer Australia
- National Cancer Institute [5T32CA009001, P60-CA105641, UM1 CA164920]
- Cancer Research UK [C12292/A20861, C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565, C1287/A11990, C5047/A8385FCCC]
- European Community [223175 (HEALTH-F2-2009-223175)]
- NIH [CA128978, CA116167, CA192393, CA176785]
- Post-Cancer GWAS initiative - the GAME-ON initiative [1U19 CA148537, 1U19 CA148065, 1U19 CA148112]
- Department of Defense [W81XWH-10-1-0341]
- Canadian Institutes of Health Research (CIHR) [CRN-87521]
- Ministry of Economic Development, Innovation and Export Trade [PSRSIIRI-701]
- Komen Foundation for the Cure
- Breast Cancer Research Foundation
- Ovarian Cancer Research Fund
- Government of Canada through Genome Canada
- Canadian Institutes of Health Research
- Ministry of Economy, Science and Innovation through Genome Quebec
- Quebec Breast Cancer Foundation
- Research Council of Lithuania [SEN-18/2015]
- Cancer Association of South Africa
- Spanish Ministry of Health - FEDER funds [PI16/00440]
- Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2014-57680-R]
- Spanish Research Network on Rare diseases (CIBERER)
- NCI of the NIH [R25CA112486, RC4CA153828]
- NCI
- Office of the Director, NIH
- Associazione Italiana Ricerca sul Cancro (AIRC) [15547, 16732, IG17734]
- Italian Association for Cancer Research (AIRC) [16933]
- European Union (European Social Fund -ESF)
- Greek national funds through the Operational Program Education and Lifelong Learning of the National Strategic Reference Framework (NSRF) -Research Funding Program of the General Secretariat for Research Technology [SYN11_10_19 NBCA]
- German Cancer Research Center
- NIHR
- University of Kansas Cancer Center [P30 CA168524]
- Kansas Bioscience Authority Eminent Scholar Program
- Chancellors Distinguished Chair in Biomedical Sciences Professorship
- Mutua Madrilena Foundation (FMMA)
- German Cancer Aid [110837]
- European Regional Development Fund
- Free State of Saxony, Germany (LIFE -Leipzig Research Centre for Civilization Diseases) [713-241202, 14505/2470, 14575/2470]
- Ligue Nationale Contre le Cancer
- Association Le cancer du sein, parlons-en! Award
- French National Institute of Cancer (INCa)
- NIH/NCI grant [P30-CA051008]
- Fisher Center for Hereditary Cancer and Clinical Genomics Research
- Swing Fore the Cure
- IWT
- Spanish Ministry of Health [PI15/00059, PI16/01292]
- CIBERONC from ISCIII (Spain) [CB-161200301]
- European Regional Development FEDER funds
- Helsinki University Hospital Research Fund
- Academy of Finland [266528]
- Finnish Cancer Society
- Sigrid Juselius Foundation
- Dutch Cancer Society [NKI1998-1854, NKI2004-3088, NKI2007-3756]
- Netherlands Organization of Scientific Research grant [NWO 91109024]
- Pink Ribbon grants [110005, 2014-187.WO76]
- BBMRI grant [NWO 184.021.007/CP46]
- Transcan grant JTC 2012 Cancer [12-054]
- Hungarian Research Grants [KTIA-OTKA CK-80745, OTKA K-112228]
- Asociacion Espanola Contra el Cancer (AECC)
- Instituto de Salud Carlos III (organismo adscrito al Ministerio de Economia y Competitividad)
- Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa [PI10/01422, PI13/00285, PIE13/00022, PI15/00854, PI16/00563]
- Institut Catala de la Salut
- Autonomous Government of Catalonia [2009SGR290, 2014SGR338]
- Icelandic Association Walking for Breast Cancer Research
- Landspitali University Hospital Research Fund
- Canadian Institutes of Health Research [CRN87521]
- Ministry of Economic Development, Innovation and Export Trade grant [PSR-SIIRI-701]
- Ministero della Salute and 5 x 100000 Istituto Oncologico Veneto grant
- NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201, CA125183]
- Cancer Center Support Grant/Core Grant [P30 CA008748]
- NCI: the Intramural Research Program of the NCI, NIH
- Westat, Inc, Rockville, MD [NO2-CP-11019-50, N02-CP-21013-63, N02-CP65504]
- Russian Federation for Basic Research [15-04-01744, 1654-00055, 17-54-12007]
- NRG Oncology [U10 CA180868]
- NRG SDMC grant [U10 CA180822]
- NRG Administrative Office [CA 27469]
- NRG Tissue Bank [CA 27469]
- NRG Statistical and Data Center [CA 37517]
- Italian Association of Cancer Research (AIRC) [14477]
- Tuscany Institute for Tumors (ITT) grant [2014-2015-2016]
- Ministry of Science, Technology and Innovation, Ministry of Higher Education [UM. C/HlR/MOHE/06]
- Ralph and Marion Falk Medical Research Trust
- Entertainment Industry Fund National Women's Cancer Research Alliance
- American Cancer Society [SIOP-06-258-01-COUN]
- National Center for Advancing Translational Sciences (NCATS) [UL1TR000124]
- Miguel Servet Progam [CP10/00617]
- [R0 1CA140323]
- [R01 CA214545]
- [FISPI05/2275]
- [NIH1R 03CA130065]
- [PBZ_KBN_122/P05/2004]
- [1R01 CA149429-01]
- [R01 CA142996]
- [1U01CA161032]
- NATIONAL CANCER INSTITUTE [ZIACP010144] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. Weevaluated whether PSVs inBRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 30 region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. Significance: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
